Privia Health Group Inc (PRVA) Fair Value & Analysis
Healthcare · US · Market cap $3.5B · ISIN US74276R1023
What is Privia Health Group Inc really worth?
Privia Health Group Inc
PRVA · US
A solid business, but trading 293% above our fair value of $5.26.
Strengths
Risks
Fair value as of: Aug 28, 2026
From 24 valuation models · updated 8 days ago
Share price −13.1% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($5.46). The favourable scenario is already priced in.
- Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 28, 2026.
How to read this chart
60‑month range $16.09 – $49.25 · fair‑value band $3.56 – $5.46 · the $20.67 price screens above the $5.26 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 28, 2026.
Analysis
Privia Health Group Inc (PRVA) currently trades at $20.67, while our model-based Fair Value estimate is $5.26, implying the stock looks roughly 292.9% overvalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of $15.94 per share, and 4 of the 24 models we run sit above the $20.67 price. Bear case: the Earnings-Based group reads lowest at $3.65, and 20 of the 24 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Privia Health Group Inc generated revenue of $2.2B at a net margin of 1.0%. Revenue grew 25.8% year over year. It earns a return on equity of 3.6%. The balance sheet holds a net cash position of $470M. Fundamentals as of Aug 28, 2026
Our scenario range runs from $3.56 (bear case) to $5.46 (bull case); at $20.67, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 22% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −64% fair-value upside, at −75%, PRVA screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $0.1155 per share, which is 2.2 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: DCF Models ($15.94) versus Earnings-Based ($3.65). Highest evidence: FCF DCF (76).
Notify me when PRVA reaches fair value
Put PRVA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 28, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 61 · Market factors (momentum, volatility) 41
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems.
Full company description
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems. It also offers technology and population health tools to enhance providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; and single-TIN medical group that facilitates negotiating power, clinical integration, and alignment of financial incentives. In addition, the company operates accountable care organization, which engages patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect across platform to better understand the holistic needs of each patient and connect with other providers to address individual medical needs. The company was founded in 2007 and is headquartered in Arlington, Virginia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Privia Health Group Inc reported revenue of $2.1B in FY2025 versus $966M in FY2021, a compound +21.7%/yr. Reported net income was $22.9M in FY2025.
PRVA screens 293% overvalued. Compare with Veeva Systems Inc →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Privia Health (PRVA): Buy, Sell, or Hold Post Q2 Earnings?
- Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors
- The Top 5 Analyst Questions From Privia Health’s Q2 Earnings Call
- Privia Health’s (PRVA) Guidance Keeps Rising, So Is The Stock Keeping Pace?
Peer Group
Health Information Services · 128 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 42/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 28, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $282.13 | $91.49 | −68% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | −87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | −64% |
| HealthEquity, Inc HQY | $104.27 | $56.63 | −46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | −72% |
| 10x Genomics, Inc TXG | $55.63 | $17.18 | −69% |
| Waystar Holding WAY | $25.76 | $12.86 | −50% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | −87% |
| Doximity, Inc DOCS | $24.74 | $25.91 | +5% |
| IKS IKS | ₹1,785 | ₹830.74 | −53% |
Compare Privia Health Group Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Privia Health Group Inc (PRVA) overvalued or undervalued?
What is the fair value of PRVA?
What is the quality score of PRVA?
What is the revenue of Privia Health Group Inc (PRVA)?
What is the net profit margin of PRVA?
Watch Privia Health Group Inc in the live analysis
One click puts Privia Health Group Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.